Non-small Cell Lung CancerPhase 2PROACC-1NCT05546476
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
A Phase 2 study testing ponsegromab in people with Non-small Cell Lung Cancer and Pancreatic Cancer, run by Pfizer at 78 sites in 11 countries.
Trial summary
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- What is being tested?
- ponsegromab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 187 participants
- Where
- 78 sitesin 11 countries
- Study dates
- 21 Nov 2022to 23 Apr 2025
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Documented active diagnosis of non-small cell lung, pancreatic, colorectal cancer
- Cachexia defined by Fearon criteria of weight loss
- Serum GDF-15 concentrations
- Signed informed consent
- ECOG PS ≤3 with life expectancy of at least 4 months to be able to complete Part A.
Who cannot join
- Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
- Current active reversible causes of decreased food intake.
- Cachexia caused by other reasons.
- History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody.
- inadequate liver function
- renal disease requiring dialysis
Trial locations and contacts
78 sites in 11 countries.
78 sites in 11 countries
United States19 sites
Pacific Cancer Medical Center INC
Anaheim, California, 92801
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808
Beverly Hills Cancer Center
Beverly Hills, California, 90211
Bozeman Health Deaconess Hospital
Bozeman, Montana, 59715
CARTI Conway
Conway, Arkansas, 72034
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
IU Health Arnett Cancer Center
Lafayette, Indiana, 47904
CARTI Cancer Center
Little Rock, Arkansas, 72205
Tandem Clinical Research
Marrero, Louisiana, 70072
CARTI North Little Rock
North Little Rock, Arkansas, 72117
Oregon Health and Science University: Center for Health and Healing 1
Portland, Oregon, 97239
Oregon Health and Science University: Center for Health and Healing 2
Portland, Oregon, 97239
Oregon Health and Science University
Portland, Oregon, 97239
Emad Ibrahim,MD,INC.
Redlands, California, 92373
Carta - Clinical Associates in Research Therapeutics of America, LLC
San Antonio, Texas, 78212
Providence Medical Foundation
Santa Rosa, California, 95403
Virginia Mason Medical Center
Seattle, Washington, 98101
CARTI Stuttgart
Stuttgart, Arkansas, 72160
Wenatchee Valley Hospital
Wenatchee, Washington, 98801
China10 sites
Peking University First Hospital
Beijing, Beijing Municipality, 100034
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, 213003
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016
Qilu Hospital of Shandong University
Jinan, Shandong, 250012
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006
Shanghai Changhai Hospital
Shanghai, Shanghai Municipality, 200433
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013
The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325035
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430030
Henan Cancer Hospital
Zhengzhou, Henan, 450008
Bulgaria8 sites
Complex Oncology Center - Burgas
Burgas, 8000
Specialized Hospital for Active Treatment of Oncology - Haskovo
Haskovo, 6300
Complex Oncology Center - Ruse EOOD
Rousse, 7002
Complex Oncology Center - Shumen
Shumen, 9700
Multiprofile Hospital for Active Treatment Serdika EOOD
Sofia, 1303
MHAT for Women's Health Nadezhda
Sofia, 1330
University Multiprofile Hospital for Active Treatment Sofiamed
Sofia, 1797
Complex Oncology Center - Vratsa
Vratsa, 3000
Japan8 sites
Hyogo Cancer Center
Akashi, Hyōgo, 673-8558
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577
University Hospital,Kyoto Prefectural University of Medicine
Kyoto, 602-8566
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, 791-0280
Shizuoka Cancer Center
Nagaizumi-cho, Shizuoka, 411-8777
Aichi Cancer Center Hospital
Nagoya, Nagoya, Aichi, 464-8681
The Cancer Institute Hospital of JFCR
Tokyo, 135-8550
Kanagawa cancer center
Yokohama, Kanagawa, 241-8515
Slovakia6 sites
Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica
Banská Bystrica, 975 17
Univerzitna nemocnica Bratislava, Nemocnica Ruzinov
Bratislava, 826 06
Narodny onkologicky ustav, II. Onkologicka klinika LFUK a NOU
Bratislava, 833 10
Fakultna nemocnica s poliklinikou Nove Zamky
Nové Zámky, 940 34
Nemocnica na okraji mesta, n.o.
Partizánske, 95801
Fakultna nemocnica Trnava
Trnava, 917 75
Spain6 sites
Institut Català d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Catalunya [cataluña], 08908
Hospital Universitario HM Sanchinarro
Madrid, 28050
Hospital Son Llàtzer
Palma, Illes Balears [islas Baleares], 07198
Hospital Universitari General de Catalunya
Sant Cugat del Vallès, Barcelona [barcelona], 08915
Fundación Instituto Valenciano de Oncología
Valencia, Valenciana, Comunitat, 46009
Hospital Universitari i Politecnic La Fe
Valencia, 46026
Taiwan5 sites
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807
China Medical University Hospital
Taichung, 404332
Chi Mei Hospital - Liouying Branch
Tainan, Tainan, 73657
National Cheng Kung University Hospital
Tainan, 704
Chang Gung Medical Foundation-Linkou Branch
Taoyuan, 333
Australia4 sites
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, 2010
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000
Orange Hospital
Orange, New South Wales, 2800
Western Health-Sunshine & Footscray Hospitals
St Albans, Victoria, 3021
Canada4 sites
CIUSSS- saguenay-Lac-Saint-Jean
Chicoutimi, Quebec, G7H 5H6
The Ottawa Hospital - General Campus
Ottawa, Ontario, K1H 8L6
Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski
Rimouski, Quebec, G5L 5T1
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9
Hungary4 sites
Semmelweis Egyetem
Budapest, 1083
Országos Korányi Pulmonológiai Intézet
Budapest, 1121
Bacs-Kiskun Varmegyei Oktatokorhaz
Kecskemét, Bács-Kiskun county, 6000
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház
Szolnok, Jász-Nagykun-Szolnok, 5004
Poland4 sites
Regionalny Szpital Specjalistyczny im. Dr. Wladyslawa Bieganskiego
Grudziądz, 86-300
NZOZ "Vegamed"
Katowice, 40-060
Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
Krakow, Lesser Poland Voivodeship, 30-348
Specjalistyczna Praktyka Lekarska Slawomir Mandziuk
Lublin, 20-093
About this study
Official title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
Read the detailed description
A 12 week double blind study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
During the initial 12-week treatment period (Part A), a total of 3 doses of ponsegromab or placebo will be administered 4 weeks apart subcutaneously. Each dose contains two injections. Part B is an optional open-label treatment period consisting of ponsegromab administered every 4 weeks subcutaneously for up to one year. Part B does not include placebo.
Assessments include:
- Body weight measurements
- Measure the impact of ponsegromab compared to placebo on physical activity.
- Measure the impact of ponsegromab compared to placebo on appetite, fatigue, nausea, vomiting and physical function questionnaires.
- Blood samples to evaluate safety and additional endpoints including the amount of study drug in the blood and the effects of the study drug on levels of GDF15
- Up to 3 additional blood samples (two samples during Part A and one sample during Part B, if relevant) in a subset of participants as part of a substudy for more comprehensive assessment of the amount of study drug in the blood and of the effects of the study drug on levels of GDF-15.
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite, Fatigue, Cachexia
- Being tested
- ponsegromab, Placebo for ponsegromab
- Keywords
- cancer, anorexia, cachexia, weight loss, loss of appetite, fatigue
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms, Anorexia, Fatigue, Cachexia, Neoplasms, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ponsegromabDrug
Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment
Placebo for ponsegromabDrug
Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment
| Study group | Role | What they receive |
|---|---|---|
| Double-Blind ponsegromab Treatment low dose followed by Open Label ponsegromab Treatment | Experimental | ponsegromab low dose subcutaneous injection every 4 weeks Receives: Drug: ponsegromab |
| Double-Blind Placebo Treatment followed by Open-Label ponsegromab Treatment | Placebo comparator | Match placebo subcutaneous injection every 4 weeks Receives: Drug: Placebo for ponsegromab |
| Double-Blind ponsegromab Treatment medium dose followed by Open Label ponsegromab Treatment | Experimental | ponsegromab medium dose subcutaneous injection every 4 weeks Receives: Drug: ponsegromab |
| Double-Blind ponsegromab Treatment high dose followed by Open Label ponsegromab Treatment | Experimental | ponsegromab high dose subcutaneous injection every 4 weeks Receives: Drug: ponsegromab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Part A: Change From Baseline in Body Weight at Week 12
Body weight was measured in kilograms using a calibrated weighing scale. Baseline was defined as the last average of the duplicate measurements prior to, or on Day 1. The average of the duplicate body weights collected at assessment time was considered. The posterior medians and 90 percent (%) credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for each randomized dose (including placebo). 4-Parameter maximal effect (E max) model: change from baseline = E 0 + (E max * dose^Hill) / (ED 50^Hill + dose^Hill), where E0 is the placebo effect, E max is the maximum effect, ED 50 is the dose producing 50% of the maximum effect, and Hill is the slope parameter. Model utilized a Bayesian methodology with a robustified, informative meta-analytic predictive prior for the placebo change from baseline at week 12.
Measured: Baseline, Week 12
Secondary outcomes (12)
Part A: Change From Baseline in Physical Activity at Week 12
Physical activity was monitored using accelerometry (wearable digital sensors). Physical activity was categorized as: sedentary activity, non-sedentary physical activity, and moderate to vigorous physical activity. In this outcome measure time for each type of physical activity per day was considered. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using mixed models repeated measures (MMRM) model.
Measured: Baseline, Week 12
Part A: Change From Baseline in Mean Activity Level During Maximum 6 Minutes at Week 12
Physical activity was monitored using accelerometry (wearable digital sensors). In this outcome measure mean activity level during maximum 6 minutes was considered. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.
Measured: Baseline, Week 12
Part A: Change From Baseline in Total Vector Magnitude at Week 12
Total vector magnitude is a measure of overall physical activity. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.
Measured: Baseline, Week 12
Part A: Change From Baseline in Gait at Week 12
Gait was monitored using accelerometry (wearable digital sensors). Analysis was performed using MMRM model. Gait included: gait speed and 95th percentile of gait speed. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.
Measured: Baseline, Week 12
Part A: Change From Baseline in Functional Assessment of Anorexia-Cachexia Therapy- Anorexia and Cachexia Subscale (FAACT-ACS) at Week 12
FAACT-ACS is a 12-item symptom-specific subscale to measure participants' concerns about their anorexia (appetite) or cachexia (weight) for past 7 days. Each item was scored from 0 to 4, where 0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, and 4= very much. The total FAACT-ACS score ranged from 0 to 48. Higher scores are associated with a higher health-related quality of life. FAACT-ACS was analyzed using an MMRM model.
Measured: Baseline (prior to dose on Day 1), Week 12
Part A: Change From Baseline in FAACT- 5-Item Anorexia Symptom Scale (5IASS) at Week 12
FAACT-5IASS is a 5-item subscale to measure participants' perceptions of anorexia (appetite) concerns for past 7 days. Each item was scored from 0 to 4, where 0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, and 4= very much. The total FAACT-5IASS score ranged from 0 to 20. Higher scores are associated with a higher health-related quality of life. FAACT-5IASS was analyzed using an MMRM model.
Measured: Baseline (prior to dose on Day 1), Week 12
Part A: Change From Baseline in Cancer-Related Cachexia Symptom Diary (CRCSD) Scores at Week 12: Appetite, Nausea and Physical Fatigue
The CRCSD is a daily, self-reported questionnaire that measured severity of symptoms related to cancer cachexia: appetite, nausea, vomiting, and fatigue. Participants rated appetite, nausea and physical fatigue symptom every day, and weekly averages were calculated over the 7 days prior, from 0 to 10, where 0 = no symptom and 10 = worst possible symptom. Higher scores indicated more severe disease. CRCSD was analyzed using an MMRM model.
Measured: Baseline, Week 12
Part A: Median Change From Baseline in CRCSD Scores at Week 12: Vomiting Frequency
The CRCSD is a daily, self-reported questionnaire that measured severity of symptoms related to cancer cachexia: vomiting frequency. Participants rated vomiting frequency over the past 24 hours, from 0 to 30, where 0 = no symptom and 30 = worst possible symptom. Higher scores indicated more severe disease.
Measured: Baseline, Week 12
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. TEAE were defined as any event that was not present before exposure to study drug, or any event already present that worsened in either intensity or frequency after exposure to study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included serious AEs and all non-SAEs.
Measured: From the first dose of study drug until first dose of open-label ponsegromab 400 mg for participants entering Part B or through Week 16 follow-up for participants not entering Part B (including 8 weeks of follow-up from last dose of study drug in part A)
Part A: Number of Participants With Incidence of Laboratory Test Abnormalities
Laboratory test abnormality parameters included: hematology- hemoglobin (gram per deciliter [g/dL]), hematocrit (%), erythrocytes (10^12/Liter [L]) less than (<) 0.8*lower limit of normal (LLN); platelets (10^9/L) <0.5*LLN to more than (>) 1.75*upper limit of normal (ULN); leukocytes (10^9/L) <0.6*LLN to >1.5*ULN; lymphocytes, neutrophils (10^9/L) <0.8*LLN to >1.2*ULN. Clinical chemistry- bilirubin, glucose (mg/dL) >1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase (Units/L [U/L]) >3.0*ULN; protein, albumin (gram [g]/dL) <0.8*LLN; urea (mmol/L) >1.3xULN; creatinine (mg/dL) >1.3*ULN; sodium (milliequivalents [mEq]/L) <0.95*LLN; potassium (mEq/L) <0.9*LLN to >1.1*ULN.
Measured: Day 1 up to Week 12
Part A: Number of Participants With Post-Baseline Vital Signs Meeting the Predefined Criteria
Vital signs criteria included: supine systolic blood pressure (SBP) <90 millimeters of mercury (mmHg), increase and decrease in change of more than or equal to (>=) 30mmHg; supine diastolic blood pressure (DBP) <50 mmHg, increase and decrease in change of >= 20mmHg; pulse rate <40 beats per minute (bpm) to >120 bpm. Only rows which included at least 1 participant in any reporting group with abnormality were reported in this outcome measure.
Measured: Day 1 up to Week 12
Part A: Number of Participants With Clinically Significant Echocardiogram (ECG) Abnormalities
ECG parameters included heart rate (HR), PR interval, QT interval, QTc corrected using Fridericia's formula (QTcF) and QRS complex. HR: RR (interval between 2 successive R waves on ECG) decrease >25% and to a VR (interval between QRS wave and T wave on ECG) >100, RR increase >25% and to a VR <50; PR interval: baseline less than or equal to (<=) 200 and % change >= 50%; QT interval: >450, >480, >500, increase from baseline >30, increase from baseline >60; QTcF: 470 < value <= 480, 480 < value <= 500, value > 500, 30 < change <= 60 and change >60; QRS complex: value >= 140, % change >=50%. Clinically significant values were determined by the investigator.
Measured: Day 1 up to Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2022
- Study start21 Nov 2022
- Primary completion13 Mar 2024
- Study completion23 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Non-small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 187 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05546476
- Sponsor's protocol ID
- C3651003
- Other IDs
- PROACC-1, 2023-510446-24-00, 2023
- Acronym
- PROACC-1
- Status last verified
- Jun 2026
- First submitted
- 12 Aug 2022
- Last updated
- 3 Jun 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Publications
Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, Hendifar AE, Fallon M, Takayama K, Asmis T, Dunne RF, Karahanoglu I, Northcott CA, Harrington MA, Rossulek M, Qiu R, Saxena AR. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024 Dec 19;391(24):2291-2303. doi: 10.1056/NEJMoa2409515. Epub 2024 Sep 14.
PubMed 39282907Groarke JD, Crawford J, Collins SM, Lubaczewski SL, Breen DM, Harrington MA, Jacobs I, Qiu R, Revkin J, Rossulek MI, Saxena AR. Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design. J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):1054-1061. doi: 10.1002/jcsm.13435. Epub 2024 Mar 18.
PubMed 38500292